LAUSR

T-cell prolymphocytic leukemia (T-PLL) is a mature T-cell leukemia typically presenting at stages of exponentially rising lymphocyte counts in peripheral blood, accompanied by splenomegaly and bone marrow involvement [1, 2]. T-PLL is inherently highly aggressive and its notoriously refractory behavior to conventional therapeutics [3, 4] adds to its very poor prognosis. Median survival times from diagnosis are usually under 2-3 years. Up until now there is not a single FDA or EMA approved substance for T-PLL. Even after responses in 80-90% of patients to the most efficient single agent, the monoclonal antibody Alemtuzumab, relapses within 1-2 years following this treatment are the rule [2, 3]. After its market retraction for repurposing in multiple sclerosis, Alemtuzumab is currently only available in a compassionate use program. Inescapably, this has already ushered the post-Alemtuzumab era in T-PLL. Moreover, consolidating allogeneic stem cell transplantation in first Editorial